GeneDx Holdings (WGSWW) Liabilities and Shareholders Equity (2020 - 2026)

GeneDx Holdings (WGSWW) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $506.3 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $506.3 million, up 13.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 billion (up 19.48% YoY), and the FY2025 annual result was $523.7 million, up 24.88% from the prior year.
• Liabilities and Shareholders Equity declined to $506.3 million in Q1 2026 per WGSWW's latest filing, from $523.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $933.3 million in Q2 2022 and troughed at $389.1 million in Q2 2024.
• A 5-year average of $510.3 million and a median of $476.4 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity soared 431.68% in 2022, then plunged 49.66% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $490.9 million in 2022, then retreated by 14.7% to $418.8 million in 2023, then grew by 0.15% to $419.4 million in 2024, then increased by 24.88% to $523.7 million in 2025, then declined by 3.32% to $506.3 million in 2026.
• Business Quant data shows WGSWW's Liabilities and Shareholders Equity at $506.3 million in Q1 2026, $523.7 million in Q4 2025, and $493.9 million in Q3 2025.